The Effect of Proton Pump Inhibitors on Barrett's Esophagus

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Proton pump inhibitors (PPIs) may protect against carcinogenesis in Barrett's esophagus because they eliminate the chronic esophageal inflammation of reflux esophagitis, and because they decrease esophageal exposure to acid, which can cause cancer-promoting DNA damage and increase proliferation in Barrett's metaplasia. Most clinical studies of PPIs and cancer development in Barrett's esophagus have found a cancer-protective effect for these drugs, although there are some contradictory data. Chemoprevention of dysplasia and cancer in Barrett's esophagus with PPIs appears to be cost-effective, and the indirect evidence supporting a cancer-protective role for PPIs is strong enough to warrant PPI treatment of virtually all patients with Barrett's esophagus.

Original languageEnglish (US)
Pages (from-to)415-424
Number of pages10
JournalGastroenterology Clinics of North America
Issue number2
StatePublished - Jun 1 2015


  • Barrett's esophagus
  • Dysplasia
  • Esophageal cancer
  • Gastroesophageal reflux disease
  • Proton pump inhibitor

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'The Effect of Proton Pump Inhibitors on Barrett's Esophagus'. Together they form a unique fingerprint.

Cite this